HCM

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: JNJ ONC ZLAB ASND NBP MGNX JSPR WWW ADAG HUYA

| Held by: SPDW CANC DFEM NSI DFAX DFSE

Scroll to Statements

Index	-	P/E	5.81	EPS (ttm)	2.62	Insider Own	2.30%	Shs Outstand	174.47M	Perf Week	-1.17%
Market Cap	2.66B	Forward P/E	33.11	EPS next Y	0.46	Insider Trans	0.00%	Shs Float	170.46M	Perf Month	4.60%
Enterprise Value	1.40B	PEG	-	EPS next Q	-	Inst Own	3.04%	Short Float	0.16%	Perf Quarter	3.18%
Income	458.03M	P/S	4.83	EPS this Y	-87.71%	Inst Trans	-1.41%	Short Ratio	8.24	Perf Half Y	-7.02%
Sales	549.97M	P/B	2.15	EPS next Y	44.07%	ROA	30.26%	Short Interest	0.28M	Perf YTD	14.33%
Book/sh	7.10	P/C	1.94	EPS next 5Y	-	ROE	45.85%	52W High	19.50 -21.85%	Perf Year	21.63%
Cash/sh	7.84	P/FCF	-	EPS past 3/5Y	- -	ROIC	35.02%	52W Low	12.18 25.17%	Perf 3Y	4.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	8.89% 19.22%	Gross Margin	38.68%	Volatility	3.01% 2.90%	Perf 5Y	-47.88%
Dividend TTM	-	EV/Sales	2.55	EPS Y/Y TTM	1119.53%	Oper. Margin	-7.14%	ATR (14)	0.49	Perf 10Y	14.59%
Dividend Ex-Date	-	Quick Ratio	4.83	Sales Y/Y TTM	-12.78%	Profit Margin	83.28%	RSI (14)	60.11	Recom	1.32
Dividend Gr. 3/5Y	- -	Current Ratio	4.96	EPS Q/Q	-88.20%	SMA20	4.86%	Beta	0.42	Target Price	21.24
Payout	0.00%	Debt/Eq	0.08	Sales Q/Q	41.96%	SMA50	4.55%	Rel Volume	0.78	Prev Close	15.16
Employees	1796	LT Debt/Eq	0.06	Earnings	Mar 05 BMO	SMA200	0.01%	Avg Volume	33.91K	Price	15.24
IPO	Mar 17, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	78.49% -15.95%	Trades		Volume	26,285	Change	0.53%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-22-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$13.75
May-13-25	Downgrade	HSBC Securities	Buy → Hold
Nov-24-23	Upgrade	Deutsche Bank	Hold → Buy
May-04-22	Downgrade	Deutsche Bank	Buy → Hold
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$46
Aug-03-21	Initiated	Jefferies	Buy	$52
Oct-02-20	Initiated	Deutsche Bank	Buy	$40
Mar-13-20	Initiated	Cantor Fitzgerald	Overweight
Feb-20-20	Initiated	Goldman	Buy
Nov-19-19	Initiated	CLSA	Buy
Oct-23-19	Reiterated	BofA/Merrill	Buy	$35 → $29
Jul-05-19	Initiated	Macquarie	Outperform

Show Previous Ratings

Apr-08-26 08:00PM	HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 (GlobeNewswire)
Mar-22-26 08:00PM	HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China (GlobeNewswire)
Mar-11-26 09:02PM	HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... (GuruFocus.com)
Mar-09-26 05:30AM	HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK in China (GlobeNewswire)
Mar-07-26 08:16AM	Hutchmed price target lowered to $21 from $22 at BofA (TipRanks)
03:30AM	Loading…
Mar-06-26 03:30AM	Intended Retirement of Independent Non-executive Director and changes of composition of board committees (GlobeNewswire)
Mar-05-26 09:07PM	HUTCHMED H2 Earnings Call Highlights (MarketBeat)
06:00AM	HUTCHMED Reports 2025 Full Year Results and Business Updates (GlobeNewswire)
Mar-04-26 03:30AM	HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors (GlobeNewswire)
Feb-06-26 03:30AM	HUTCHMED to Announce 2025 Final Results (GlobeNewswire)
Feb-02-26 07:49PM	Paycom Software, Inc. (PAYC): A Bull Case Theory (Insider Monkey)
Jan-13-26 11:00PM	HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet (GlobeNewswire)
Jan-07-26 09:55AM	Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should Know (Zacks) +6.62%
Jan-06-26 07:00PM	HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China (GlobeNewswire)
Jan-04-26 07:00PM	HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
05:00AM	Loading…
Dec-30-25 05:00AM	HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification (GlobeNewswire)
Dec-29-25 03:35AM	HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma (GlobeNewswire)
Dec-16-25 07:00PM	HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors (GlobeNewswire)
Dec-07-25 07:00PM	HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China (GlobeNewswire)
Nov-26-25 07:00PM	HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting (GlobeNewswire)
Nov-04-25 07:00PM	HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS and TAGRISSO Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO (GlobeNewswire)
Nov-02-25 07:00PM	HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event (GlobeNewswire)
Oct-22-25 08:00PM	HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-14-25 04:30AM	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee (GlobeNewswire)
Oct-13-25 12:00AM	HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress (GlobeNewswire)
Oct-01-25 08:00PM	HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 (GlobeNewswire)
Sep-11-25 08:00PM	Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025 (GlobeNewswire) +9.53%
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire)
Sep-04-25 08:00PM	HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 (GlobeNewswire) +7.61%
Aug-24-25 08:20PM	HUTCHMED Announces Appointment of Acting Chief Executive Officer (GlobeNewswire)
08:00PM	Loading…
Aug-19-25 08:00PM	HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS and TAGRISSO Combination as a First-Line Therapy for Certain Lung Cancer Patients in China (GlobeNewswire)
10:00AM	Best Momentum Stock to Buy for August 19th (Zacks)
Aug-07-25 07:00AM	HUTCHMED Reports 2025 Interim Results (GlobeNewswire) -9.01%
Jul-03-25 04:30AM	HUTCHMED to Announce 2025 Half-Year Financial Results (GlobeNewswire)
Jun-30-25 04:30AM	HUTCHMED Announces China Approval for ORPATHYS in Combination with TAGRISSO for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy (GlobeNewswire)
Jun-23-25 09:55AM	How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52% (Zacks)
Jun-05-25 09:55AM	Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High? (Zacks)
Jun-04-25 07:45PM	HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma (GlobeNewswire)
Jun-01-25 08:00PM	HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting (GlobeNewswire)
May-22-25 08:00PM	HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting (GlobeNewswire)
May-16-25 08:35AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
May-13-25 03:00AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire) -5.60%
May-12-25 08:00PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
May-08-25 10:44AM	UPDATE - International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
08:35AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
Apr-23-25 08:00PM	HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-21-25 08:00PM	HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China (GlobeNewswire) +12.31%
Mar-21-25 06:00AM	HUTCHMED Announces NMPA Conditional Approval for TAZVERIK (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma (GlobeNewswire) -7.07%
Mar-20-25 05:30AM	Intended Retirement of Independent Non-executive Directors and changes of composition of board committees (GlobeNewswire)
03:01AM	HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ... (GuruFocus.com)
Mar-19-25 08:00PM	HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 (GlobeNewswire) +8.23%
12:17PM	HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:00AM	HUTCHMED Reports 2024 Full Year Results and Provides Business Updates (GlobeNewswire)
Mar-18-25 08:00PM	HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China (GlobeNewswire)
Mar-06-25 05:00AM	HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China (GlobeNewswire)
Mar-05-25 05:00AM	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee (GlobeNewswire)
Feb-19-25 03:30AM	HUTCHMED to Announce 2024 Final Results (GlobeNewswire) +8.09%
Feb-12-25 10:25AM	Hutchmed price target raised to $27 from $26 at BofA (TipRanks)
Jan-13-25 11:00PM	HUTCHMED Announces NMPA Full Approval for ORPATHYS (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC (GlobeNewswire)
Jan-02-25 09:15AM	Hutchmed divests 45% interest in Shanghai Hutchison for $608M (TipRanks)
Jan-01-25 07:00PM	HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS and TAGRISSO Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy (GlobeNewswire)
05:46AM	HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture (GlobeNewswire)
Dec-12-24 07:00PM	HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA (fruquintinib) (GlobeNewswire)
Dec-11-24 11:00PM	HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy (GlobeNewswire)
Dec-03-24 07:00PM	Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT (Sintilimab Injection) in Combination with ELUNATE (Fruquintinib) for the Treatment of Advanced Endometrial Cancer (PR Newswire)
05:00AM	HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE (Fruquintinib) in Combination with TYVYT (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer (GlobeNewswire)
Nov-28-24 05:30AM	HUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at Current Terms (GlobeNewswire)
Nov-21-24 11:30PM	HUTCHMED Announces Launch by Takeda of FRUZAQLA (fruquintinib) in Japan (GlobeNewswire)
Nov-20-24 04:30AM	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee (GlobeNewswire) +7.22%
Nov-05-24 11:00PM	HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress (GlobeNewswire)
Oct-31-24 04:30AM	HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda (GlobeNewswire) -5.01%
Oct-16-24 12:30AM	HUTCHMED Announces that TAGRISSO plus ORPATHYS demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial (GlobeNewswire) +5.32%
Oct-09-24 03:30PM	HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ... (GuruFocus.com)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +5.31%
Sep-26-24 08:51AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire) +5.32%
Sep-24-24 03:00AM	HUTCHMED Announces Japan Approval for FRUZAQLA (fruquintinib) Received by Takeda (GlobeNewswire) +5.15%
Sep-19-24 02:30AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-17-24 11:22AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-08-24 08:00PM	HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer (GlobeNewswire)
Aug-30-24 12:30AM	HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China (GlobeNewswire)
Aug-28-24 12:24PM	HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers (Insider Monkey)
Aug-21-24 04:30AM	HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia (GlobeNewswire)
Jul-31-24 07:00AM	HUTCHMED Reports 2024 Interim Results and Provides Business Updates (GlobeNewswire) +8.00%
Jul-03-24 08:00PM	HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status (GlobeNewswire) +5.37%
Jun-26-24 04:30AM	HUTCHMED to Announce 2024 Half-Year Financial Results (GlobeNewswire)
Jun-24-24 05:30AM	Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 (GlobeNewswire)
Jun-21-24 04:00PM	HUTCHMED Announces European Commission Approval for FRUZAQLA (fruquintinib) Received by Takeda (GlobeNewswire)
Jun-16-24 08:00PM	HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology (GlobeNewswire)
Jun-06-24 08:00PM	HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China (GlobeNewswire)
Jun-02-24 08:00PM	HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine (GlobeNewswire)
May-23-24 08:00PM	HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting (GlobeNewswire)
May-17-24 10:00AM	HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees (GlobeNewswire)
May-16-24 08:00PM	HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress (GlobeNewswire)
May-13-24 08:00PM	HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China (GlobeNewswire)
08:00PM	HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui (GlobeNewswire)
08:00PM	HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui (GlobeNewswire)
May-08-24 04:30AM	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee (GlobeNewswire)
Apr-30-24 12:00PM	HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect? (Zacks)
Apr-26-24 08:30AM	HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda (GlobeNewswire)

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HUTCHMED (China) Limited ADR

Upgrade your Finviz experience